JP2023535074A5 - - Google Patents

Info

Publication number
JP2023535074A5
JP2023535074A5 JP2023504636A JP2023504636A JP2023535074A5 JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5 JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5
Authority
JP
Japan
Prior art keywords
complex according
disease
antibody
myopathy
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023504636A
Other languages
English (en)
Japanese (ja)
Other versions
JP7828947B2 (ja
JP2023535074A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041003 external-priority patent/WO2022020108A1/en
Publication of JP2023535074A publication Critical patent/JP2023535074A/ja
Publication of JP2023535074A5 publication Critical patent/JP2023535074A5/ja
Priority to JP2026032104A priority Critical patent/JP2026102651A/ja
Application granted granted Critical
Publication of JP7828947B2 publication Critical patent/JP7828947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504636A 2020-07-23 2021-07-09 筋標的化複合体およびそれらの使用 Active JP7828947B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032104A JP2026102651A (ja) 2020-07-23 2026-03-02 筋標的化複合体およびそれらの使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063055785P 2020-07-23 2020-07-23
US63/055,785 2020-07-23
US202063061842P 2020-08-06 2020-08-06
US63/061,842 2020-08-06
US202063069078P 2020-08-23 2020-08-23
US63/069,078 2020-08-23
US202163143831P 2021-01-30 2021-01-30
US63/143,831 2021-01-30
US202163181450P 2021-04-29 2021-04-29
US63/181,450 2021-04-29
PCT/US2021/041003 WO2022020108A1 (en) 2020-07-23 2021-07-09 Muscle-targeting complexes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032104A Division JP2026102651A (ja) 2020-07-23 2026-03-02 筋標的化複合体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2023535074A JP2023535074A (ja) 2023-08-15
JP2023535074A5 true JP2023535074A5 (cg-RX-API-DMAC7.html) 2024-07-18
JP7828947B2 JP7828947B2 (ja) 2026-03-12

Family

ID=79728348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504636A Active JP7828947B2 (ja) 2020-07-23 2021-07-09 筋標的化複合体およびそれらの使用
JP2026032104A Pending JP2026102651A (ja) 2020-07-23 2026-03-02 筋標的化複合体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032104A Pending JP2026102651A (ja) 2020-07-23 2026-03-02 筋標的化複合体およびそれらの使用

Country Status (7)

Country Link
US (1) US20230287108A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185329A4 (cg-RX-API-DMAC7.html)
JP (2) JP7828947B2 (cg-RX-API-DMAC7.html)
CN (2) CN121270701A (cg-RX-API-DMAC7.html)
AU (1) AU2021313058A1 (cg-RX-API-DMAC7.html)
CA (1) CA3186755A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022020108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
CN116096890A (zh) 2020-04-02 2023-05-09 米雷楚莱股份有限公司 使用工程化寡核苷酸的靶向抑制
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3222816A1 (en) * 2021-06-21 2022-12-29 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
JPWO2022270585A1 (cg-RX-API-DMAC7.html) 2021-06-23 2022-12-29
CA3226301A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP4366774A4 (en) * 2021-07-09 2025-11-19 Dyne Therapeutics Inc MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
WO2023168427A1 (en) * 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
US12527877B2 (en) 2024-01-24 2026-01-20 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
WO2025215092A1 (en) * 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734799B2 (en) * 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
AU2011349443B2 (en) * 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
UY37523A (es) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
PE20210125A1 (es) 2017-10-14 2021-01-19 Abbvie Inc Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AU2019315593B2 (en) * 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
EP3829594A4 (en) * 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2020028832A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP7700039B2 (ja) * 2019-01-04 2025-06-30 マレンゴ・セラピューティクス,インコーポレーテッド 抗tcr抗体分子およびその使用
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
MX2023000958A (es) * 2020-07-23 2023-04-14 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
US20230256112A1 (en) * 2020-07-23 2023-08-17 Dyne Therapeutics, lnc. Anti-transferrin receptor (tfr) antibody and uses thereof
CN116348139A (zh) * 2020-07-23 2023-06-27 达因疗法公司 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途

Similar Documents

Publication Publication Date Title
CN116194470B (zh) 肌肉靶向复合物及其用途
JP2023535444A5 (cg-RX-API-DMAC7.html)
CN114025805B (zh) 制备蛋白质-寡核苷酸复合物的方法
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2023510351A5 (cg-RX-API-DMAC7.html)
CN116368150A (zh) 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
Ivanova et al. Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle
JP2025067909A5 (cg-RX-API-DMAC7.html)
JP2021533200A5 (cg-RX-API-DMAC7.html)
JP2021533198A5 (cg-RX-API-DMAC7.html)
JP2023512442A5 (cg-RX-API-DMAC7.html)
CN116348138A (zh) 抗转铁蛋白受体(tfr)抗体及其用途
JP2021532832A5 (cg-RX-API-DMAC7.html)
JP2024525614A5 (cg-RX-API-DMAC7.html)
CN112912399A (zh) 肌肉靶向复合物及其用于治疗蓬佩病的用途
JP2021533199A5 (cg-RX-API-DMAC7.html)
CN112930197A (zh) 肌肉靶向复合物及其用途
JP2021533197A5 (cg-RX-API-DMAC7.html)
CN112955153A (zh) 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
JP2023509793A5 (cg-RX-API-DMAC7.html)
CN112955154A (zh) 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2008527993A (ja) 特異性及び送達の改善のためのsiRNA分子、shRNA分子又はアンチセンス分子及び機能的実体を含む複合体
CN116438304A (zh) 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
CN113164620A (zh) 肌肉靶向复合物及其用于治疗进行性骨化性纤维结构不良的用途